Actor portrayal of an Opdualag® patient with their partner. A first treatment for advanced melanoma regardless of BRAF biomarker status.

Opdualag is a combination of 2 immunotherapy medicines
that works with your own immune system to help fight
advanced melanoma, a type of metastatic skin cancer

Nivolumab and relatlimab-rmbw (Opdualag®) is included in the National Comprehensive Cancer Network (NCCN®) recommendations as a first-line or second-line treatment option for metastatic melanoma.*

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are developed by experts in leading cancer centers. The guidelines are tools that healthcare providers use to provide the best cancer care to patients.

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma: Cutaneous V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed September 16, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

braf_gene_content

Are you familiar with BRAF gene biomarker testing in melanoma, a type of skin cancer ?

Opdualag® patients and caregivers can access useful resources, videos, and support.

Explore resources, patient videos, and find support 

Patients and caregivers can discover helpful resources, watch inspirational videos, and learn about treatment support. 



© 2025 Bristol-Myers Squibb Company.
Opdualag®, Access Support®, Opdualag™ with You, and the related logos are trademarks of Bristol-Myers Squibb Company.

This site is intended for U.S. residents 18 years of age or older.

1425-US-2500035  09/25